Another four IPOs complete busy week as biotech raise continues to match 2020's record pace
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
One of the busiest IPO weeks of the year has capped off with another four biotechs expected to make their public debuts Friday.
After Lyell, Verve and Molecular Partners all priced earlier in the week, ATAI Life Sciences, Century Therapeutics, Ambrx Biopharma and Cyteir Therapeutics each followed suit with nine-figure raises after market close Thursday. All that effort has driven the combined biotech IPO raise close to $9 billion, per the Endpoints News tally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.